论文部分内容阅读
目的 :探讨13 1I标记的美罗华用于CD2 0表达阳性的晚期难治非何杰金淋巴瘤 (NHL)患者治疗的疗效。方法 :15例晚期NHL患者 ,年龄 4 6~ 6 8岁 ,以剂量为 5 0~ 10 0Bq的13 1I作为标记物标记 10 0mg的Rituxan ,按剂量的 1/ 3直接注射于局部病灶 ,2 / 3静脉滴注。每 2~ 3个月 1次 ,2~ 3次为 1疗程。结果 :完全缓解 (CR)者 5例 ,部分缓解 (PR)者 7例 ,病情稳定(SD)者 2例 ,病情进展 (PD)者 1例 ,总有效率 (ORR) 80 %。定期检查患者血清HAMA ,未发现阳性者。结论 :13 1I标记的美罗华是NHL极有前景的治疗方法。
Objective: To investigate the efficacy of 131I-labeled rituximab in the treatment of advanced refractory non-Hodgkin’s lymphoma (NHL) patients with CD20 positive expression. Methods: Fifteen patients with advanced NHL were aged 46 to 68 years old. Rituxan (10 0 mg) was labeled with 13 1 I at a dose of 50 to 100 Bq and was directly injected into the local lesion at a dose of 1 / 3 intravenous drip. Every 2 to 3 months 1, 2 to 3 times for a course of treatment. Results: There were 5 patients with complete remission (CR), 7 patients with partial remission (PR), 2 patients with stable disease (SD) and 1 patient with progressive disease (PD). The total effective rate (ORR) was 80%. Regular examination of patients with serum HAMA, no positive. Conclusion: 131I-labeled rituximab is a promising treatment for NHL.